Lasofoxifene Tartrate not checked
Azure Biotech Inc. · AZU-101
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Vulvo Vaginal Atrophy (VVA)
- Main trialPhase 2
- “Study Objectives: Primary: • To assess the safety, tolerability, and systemic pharmacokinetics (PK) of AZU-101 Secondary: • To evaluate efficacy of daily vaginal doses of AZU-101 in postmenopausal women on vaginal epithelium”In the company’s words, NCT06197568 on ClinicalTrials.gov
- Other names
- AZU-101
Other drugs for Vulvo Vaginal Atrophy (VVA)
- Teverelix DPAntev Ltd. · Phase 2
Coming up1
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2026 | Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026